Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 2015

Czech version

Authors: P. Obrtlíková ¹; R. Urbanová ²
Authors‘ workplace: I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze ¹; Hemato‑ onkologická klinika LF UP a FN Olomouc ²
Published in: Klin Onkol 2015; 28(Supplementum 3): 22-29
doi: https://doi.org/10.14735/amko20153S22

Overview

Chemotherapy combinations with monoclonal antibodies are now the basis for treatment of chronic lymphocytic leukemia. Rituximab, the most widely used anti‑CD20 antibody in routine clinical practice, led not only to improvement of progression‑free survival, but also to improvement of overall survival in previously untreated patients with good performance status in combination with fludarabine and cyclophosphamide. This regimen has become the standard treatment for patients in good physical condition. Rituximab and the newest anti‑CD20 antibody obinutuzumab in combination with chlorambucil, as compared with chlorambucil alone, prolonged overall survival in previously untreated patients with significant comorbidities, and the combination of anti‑CD20 antibody with chlorambucil has become the standard regimen in this group of patients. Alemtuzumab and ofatumumab improved treatment results in refractory chronic lymphocytic leukemia. Targeted therapy with combination chemotherapy and monoclonal antibody in patients with chronic lymphocytic leukemia represents a significant advance in the treatment of this disease.

Key words:
monoclonal antibody – rituximab – ofatumumab – alemtuzumab – obinutuzumab

This study was supported by the program PRVOUK P27/LF1/1 and grant IGA-LF-2015-001.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
28. 7. 2015

Accepted:
2. 8. 2015

Sources

1. Glennie MJ, French RR, Cragg MS et al. Mechanisms of killing by anti‑CD20 monoclonal antibodies. Mol Immunol 2007; 44(16): 3823– 3337.

2. Cragg MS, Walshe CA, Ivanov AO et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140– 174.

3. Beers SA, Chan CH, French RR et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Sem Hematol 2010; 47(2): 107– 114.

4. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55(2): 188– 196.

5. Tam CS, O‘Brien S, Wierda W et al. Long‑term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112(4): 975– 980. doi: 10.1182/ blood‑ 2008‑ 02‑ 140582.

6. Hallek M, Fischer K, Fingerle‑ Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open‑ label, phase 3 trial. Lancet 2010; 376(9747): 1164– 1174. doi: 10.1016/ S0140‑ 6736(10)61381‑ 5.

7. Robak T, Dmoszynska A, Solal‑ Celigny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression‑free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28(10): 1756– 1765. doi: 10.1200/ JCO.2009.26.4556.

8. Foon KA, Boyiadzis M, Land SR et al. Chemoimmunotherapy with low‑dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27(4): 498– 503. doi: 10.1200/ JCO.2008.17.2619.

9. Smolej L, Brychtova Y, Doubek M at al. Low‑dose FCR is a safe and effective treatment option for elderly/ comorbid patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma. Updated results of project Q‑ Lite by Czech CLL Study Group. 56th ASH Annual Meeting and Exposition 2014: abstr. 4760.

10. Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab in patients with relapsed and/ or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29(26): 3559– 3566. doi: 10.1200/ JCO.2010.33.8061.

11. Fischer K, Cramer P, Busch R et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30(26): 3209– 3216. doi: 10.1200/ JCO.2011.39.2688.

12. Eichhorst B, Fink AM, Busch R et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and Rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and Rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic leukemia (CLL): final analysis of an International, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (ASH Annual Meeting Abstracts) 2014; 124(21): 19.

13. Parikh SA, Keating MJ, O‘Brien S et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high‑risk chronic lymphocytic leukemia. Blood 2011; 118(8): 2062– 2068. doi: 10.1182/ blood‑ 2011‑ 01‑ 329177.

14. Goede V, Fischer K, Busch R et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370(12): 1101– 1110. doi: 10.1056/ NEJMoa1313984.

15. Smolej L, Doubek M, Panovska A et al. Rituximab in combination with high‑dose dexamethasone for the treatment of relapsed/ refractory chronic lymphocytic leukemia. Leuk Res 2012; 36(10): 1278– 1282. doi: 10.1016/ j.leukres.2012.07.005.

16. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344(1): 68– 69.

17. Assouline S, Buchcheri V, Delmer A. et al. Non‑ inferior pharmacokinetics with comparable safety and response rates for subcutaneous, compared with intravenous, rituximab in combination with fludarabine and cyclophosphamide in patients with untreated chronic lymphocytic leukemia: part 2 of the phase Ib SAWYER study (BO25341). 56th ASH Annual Meeting and Exposition 2014: abstr. 1995.

18. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non‑Hodgkin lymphomas. Blood 2004; 104(6): 1793– 1800.

19. Beum PV, Lindorfer MA, Beurskens F et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008; 181(1): 822– 832.

20. Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti‑CD20 antibody, in patients with relapsed or refractory B‑ cell chronic lymphocytic leukemia: a phase 1– 2 study. Blood 2008; 111(3): 1094– 1100.

21. Osterborg A. Ofatumumab, a human anti‑CD20 monoclonal antibody. Expert Opin Biol Ther 2010; 10(3): 439– 449. doi: 10.1517/ 14712590903586239.

22. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single‑agent CD20 immunotherapy in fludarabine‑ refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28(10): 1749– 1755. doi: 10.1200/ JCO.2009.25.3187.

23. Wierda WG, Padmanabhan S, Chan GW et al. Ofatumumab is active in patients with fludarabine‑ refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011; 118(19): 5126– 5129. doi: 10.1182/ blood‑ 2011‑ 04‑ 348656.

24. Hillmen P, Robak T, Janssens A et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III Study Complement 1 (OMB110911). 55th ASH Annual Meeting and Exposition 2013: abstr. 528.

25. Offner FP, Afanasyev B et al. Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB115991. iwCLL 2013: abstr. 429.

26. Doubek M, Brychtova Y, Panovska A et al. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: results from a phase II study. Am J Hematol 2015; 90(5): 417– 421. doi: 10.1002/ ajh.23964.

27. Flynn JM, Byrd JC. Campath‑ 1H monoclonal antibody therapy. Curr Opin Oncol 2000; 12(6): 574– 581.

28. Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH‑ 1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15(4): 1567– 1574.

29. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath‑ 1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99(10): 3554– 3561.

30. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20(18): 3891– 3897.

31. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first‑line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25(35): 5616– 5623.

32. Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B‑ cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23(28): 7024– 7031.

33. Elter T, Gercheva‑ Kyuchukova L, Pylylpenko H et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011; 12(13): 1204– 1213. doi: 10.1016/ S1470‑ 2045(11)70242‑ X.

34. Lepretre S, Aurran T, Mahe B et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012; 119(22): 5104– 5110. doi: 10.1182/ blood‑ 2011‑ 07‑ 365437.

35. Stilgenbauer S, Döhner H. Campath‑ 1H‑induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347(6): 452– 453.

36. Mossner E, Brunker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti‑CD20 antibody with enhanced direct and immune effector cell‑ mediated B‑ cell cytotoxicity. Blood 2010; 115(22): 4393– 4402. doi: 10.1182/ blood‑ 2009‑ 06‑ 225979.

37. Ferrara C, Brunker P, Suter T et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co‑ expression of heterologous beta1, 4- N‑ acetylglucosaminyltransferase III and Golgi alpha‑ mannosidase II. Biotechnol Bioeng 2006; 93(5): 851– 861.

38. Herter S, Herting F, Mundigl O et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12(10): 2031– 2042. doi: 10.1158/ 1535‑ 7163.MCT‑ 12‑ 1182.

39. Dalle S, Reslan L, Besseyre de Horts T et al. Preclinical studies on the mechanism of action and the anti‑lymphoma activity of the novel anti‑CD20 antibody GA101. Mol Cancer Ther 2011; 10(1): 178– 185. doi: 10.1158/ 1535‑ 7163.MCT‑ 10‑ 0385.

40. Alduaij W, Ivanov A, Honeychurch J et al. Novel type II anti‑CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin‑dependent, lysosome‑ mediated cell death in B‑ cell malignancies. Blood 2011; 117(17): 4519– 4529. doi: 10.1182/ blood‑ 2010‑ 07‑ 296913.

41. Rafiq S, Butchar JP, Cheney C et al. Comparative assessment of clinically utilized CD20- directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 2013; 190(6): 2702– 2711. doi: 10.4049/ jimmunol.1202588.

42. Niederfellner G, Lammens A, Mundigl O et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/ II distinction of CD20 antibodies. Blood 2011; 118(2): 358– 367. doi: 10.1182/ blood‑ 2010‑ 09‑ 305847.

43. Kern DJ, James BR, Blackwell S et al. GA101 induces NK‑ cell activation and antibody‑ dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma 2013; 54(11): 2500– 2505. doi: 10.3109/ 10428194.2013.781169.

44. Cragg MS. CD20 antibodies: doing the time warp. Blood 2011; 118(2): 219– 220. doi: 10.1182/ blood‑ 2011‑ 04‑ 346700.

45. Cheadle EJ, Sidon L, Dovedi SJ et al. The induction of immunogenic cell death by type II anti‑CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. Br J Haematol 2013; 162(6): 842– 845. doi: 10.1111/ bjh.12427.

46. Klein C, Lammens A, Schafer W et al. Response to: monoclonal antibodies targeting CD20. MAbs 2013; 5(3): 337– 338. doi: 10.4161/ mabs.24108.

47. Cartron G, de Guibert S, Dilhuydy MS et al. Obinutuzumab (GA101) in relapsed/ refractory chronic lymphocytic leukemia: final data from the phase 1/ 2 GAUGUIN study. Blood 2014; 124(14): 2196– 2202. doi: 10.1182/ blood‑ 2014‑ 07‑ 586610.

48. Sehn LH, Assouline SE, Stewart DA et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20- positive B‑ cell malignancies. Blood 2012; 119(22): 5118– 5125. doi: 10.1182/ blood‑ 2012‑ 02‑ 408773.

49. Flynn JM, Kipps TJ, Boxer M et al. Obinutuzumab (GA101) 1000 mg vs 2000 mg in patients with chronic lymphocytic leukemia (CLL) results of the phase 2 GAGE (GAO4768g) trial. J Clin Oncol 2014; 32 (Suppl): abstr. 7083.

50. Brown JR, O‘Brien S, Kingsley CD et al. Obinutuzumab plus fludarabine/ cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood 2015; 125(18): 2779– 2785. doi: 10.1182/ blood‑ 2014‑ 12‑ 613570.

51. Goede V, Fischer K, Engelke A et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015; 29(7): 1602– 1604. doi: 10.1038/ leu.2015.14.

52. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B‑ cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19(8): 2153– 2164.

53. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 2010; 14(2): E10– E21. doi: 10.1188/ 10.CJON.E10‑ E21.

54. Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B‑ cell non‑hodgkin‘s lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat 2015; 38(4): 185– 192. doi: 10.1159/ 000381524.

55. Obinutuzumab (Gazyvaro) [homepage on the Internet]. Summary of product characteristics. 2014. Available from: http:/ / www.ema.europa.eu/ docs/ en_GB/ document_library/ EPAR_– _Public_assessment_report/ human/ 002799/ WC500171596.pdf.

56. Ladyzynski P, Molik M, Foltynski P. A network meta‑analysis of progression free survival and overall survival in first‑line treatment of chronic lymphocytic leukemia. Cancer Treat Rev 2015; 41(2): 77– 93. doi: 10.1016/ j.ctrv.2014.11.004.

57. Jak M, van Bochove GG, Reits EA et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti‑CD20 mAb GA101. Blood 2011; 118(19): 5178– 5188. doi: 10.1182/blood‑ 2011‑ 01‑ 331702.